A recent study has found that U.S. Special Forces veterans who underwent psychedelic treatment had lower levels of PTSD and alcohol misuse. Military veterans are much more likely to experience mental health conditions such as PTSD and depression, but existing treatments aren’t always effective.
Psychedelics are poised to play a major role in the evolution of the psychiatric industry over the next decade as researchers work to develop safer and more effective treatments. Research into psychedelic drugs including psilocybin, mescaline and MDMA has found that they can alleviate the symptoms of several mental health conditions with minimal side effects.
Hallucinogenics’ ability to treat conditions such as major depressive disorder and post-traumatic stress disorder (PTSD) makes them especially beneficial for treating veterans who tend to have mental health conditions at much higher rates than the general population. A The new study sought to determine how U.S. Special Operations Forces veterans responded to 5-MeO-DMT and ibogaine therapy.
Researchers found a “significant reduction” in alcohol misuse disorder only a month after the veterans started treatment. Furthermore, these effects lasted for six months after the first treatment session. The researchers also determined that the therapy caused a “strong reduction” in PTSD symptoms.
Soldiers who survive wars often come back home with severe psychological scars. In fact, 7 in 100 veterans are estimated to develop PTSD eventually, and 20% of military vets deal with depression. PTSD from taking part in war often involves flashbacks to traumatic experiences, frightening thoughts, bad dreams, emotional numbing and other symptoms. Many veterans turn to alcohol to cope with these effects, leading to high rates of alcohol misuse among military veterans.
Clinical psychologist and postdoctoral scholar at Ohio State University’s Center for Psychedelic Drug Research and Education Stacey Armstrong is one of the study’s authors; she has worked as a trauma psychologist for several years. In her years of practice, she worked with many people, including military vets, who had been “exposed to atrociously traumatic experiences.”
Armstrong said that many patients did not respond positively to traditional treatments, which has increased her interest in the nascent field of psychedelic-assisted therapy. She and her colleagues reviewed data collected in a Mexican clinical treatment program from 45 male Special Forces vets undergoing treatment with 5-MeO-DMT and ibogaine. They noted that the patients reported major reductions in PTSD symptom severity and alcohol drinking levels. The researchers also noticed a significant cognitive functioning improvement that remained half a year after treatment. They published their findings in the “Military Psychology” journal.
As companies within the psychedelic industry such as Compass Pathways PLC (NASDAQ: CMPS) delve further into these hallucinogenic substances, we are likely to learn more about the different ways through which these compounds work.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
According to a recent study, individuals who have used classic psychedelics like LSD or psilocybin…
There is a growing trend in which parents take tiny doses of psychedelics like LSD…
Walter Reed National Military Medical Center officials confirmed they are awaiting a $4.9m grant to…
A new study has found that while all ethnic and racial groups can benefit from…
A new study that is yet to be peer-reviewed has found that rats given psilocybin…
The American embassy in Peru has warned Americans against taking traditional psychedelics like the ayahuasca…